Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 9/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.45 |
| ▸ | CDC7 | O00311 | 6/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.43 |
| ▸ | PIM1 | P11309 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | MARK3 | P27448 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424426 | 1.00 | HDAC6 (0.52) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25386557 | 0.86 | HDAC6 (0.40) | HDAC6PIM1 | |
| SCHEMBL30424439 | 0.86 | HDAC6 (0.40) | HDAC6PIM1 | |
| SCHEMBL30425392 | 0.84 | HDAC6 (0.50) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25260165 | 0.84 | HDAC6 (0.50) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25351569 | 0.83 | HDAC6 (0.55) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL30425545 | 0.82 | HDAC6 (0.53) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25211509 | 0.82 | HDAC6 (0.51) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25251038 | 0.82 | HDAC6 (0.53) | HDAC6GSK3BROCK2CDC7AURKB | |
| SCHEMBL25355210 | 0.81 | ROCK2 (0.70) | HDAC6GSK3BROCK2CDC7AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | claimed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885GSK3B 116/4885ROCK2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.